Can gene therapies for haemophilia defend their high price tags?
Pharmaceutical Technology
NOVEMBER 9, 2022
In its October 28 quarterly Securities and Exchange Commission (SEC) filing, the company said that Roctavian’s commercial launch is now underway. million price tag. The post Can gene therapies for haemophilia defend their high price tags? BioMarin previously said that the treatment’s European price would likely be around EUR1.5
Let's personalize your content